Description The function of antigen is highly dependent on the three-dimensional structure of the protein. CanSinoBIO has built a computer-aided vaccine design platform. Based on the platform we can predict the protein structure, epitope, immunogenicity, stability, interactions, and other important characteristics from DNA sequences. We have used the technology to design pneumococcal protein antigens and develop new recombinant strains to produce a new generation of pertussis vaccines and so on.Virus-Like Particle (VLP) vaccines is assembled from recombinant expressed structural protein to form a unique spatial three-dimensional structure. The 3D structure of VLP vaccine is similar to that of most infectious viral pathogens, and can mimic the viral pathogens to present the antigen epitope to the immune system. Therefore, VLP vaccines can be easily recognized by the immune system and have high immunogenicity. CanSinoBIO has established a multi-subunit VLP expression platform through computer-aided antigen design technology, and has strong capabilities in VLP vaccine development, production, characterization and analysis.

Description Vaccine is kind of bioprodoct with the complex compositions. A thorough study and understanding of vaccine formulation are essential to ensure its safety, efficacy, and stability. CanSinoBIO is committed to doing the research of vaccine preparation to make the products to be free of phenol and preservatives free. This feature ensures a stable product quality and reduces the risk of potential side effects. Currently, we have established the development technology for vaccine preparation, new adjuvants and delivery systems, and also has a complete and advanced technology platforms for preparation, adjuvant preparation, delivery system and evaluation platform for mucosal drug.

Description The primary duties of the Nomination Committee are to make recommendations to our Board on the appointment and removal of Directors of our Company. The Nomination Committee consists of five members, namely Mr. Jianzhong LIU, Mr. Chi Shing LI, Mr. Shuifa GUI, Mr. Yiu Leung Andy CHEUNG and Dr. Xuefeng YU. Mr. Jianzhong LIU has been appointed as the chairman of the Nomination Committee.

Description We always encouraged staffs to realize self-worth in their work. So we provide opportunities for anyone who dares to challenge themselves. If you are brave enough to challenge yourself, then we will provide you best chance to enjoy it.

Description We always believed that the power from the staffs. Every staff could be a “Bole” , to render a contribution for Cansino. We have a complete internal recommendation system, make you to become a real "Bole".

Description

Description CanSino Biologics Inc. Telephone：400-922-2099； Fax：022-58213677； E-mail: info@cansinotech.com； Ad5-EBOV Consult：022-58213613 Ad5-EBOV E-mail : ebov@cansinotech.com

Description At CanSinoBIO, our main research and development focus is vaccines. To this end, we apply our expertise across a range targets from antigen discovery, antigen overexpression, purification and formulation to proof-of-concept pre-clinical evaluation, production process development and assay development.

Description

Description NDA for MCV2 was accepted by NMPA;
Listed on the Main Boary of HKEx;
NDA for MCV4 was granted with Priority Review designation